Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Quick Listen: Scrip’s Five Must-Know Things

Executive Summary

Join us for a quick audio roundup of major events in the global biopharma industry over the past week, as reported by Scrip.

Take a brief audio tour around Scrip's Five Must-Know Things, in this episode covering key developments in the business week ended 11 September 2020. 

In focus this time are a high-profile pause in a closely-watched coronavirus vaccine trial, one CEO's views on the pricing of COVID-19 interventions, a big Chinese oncology deal, promising results in asthma and an update on the fast-evolving migraine market.

Stories mentioned in this episode:

(Also see "AZ Exercises Caution With COVID Vaccine Safety Pause As Questions Remain Over Vector" - Scrip, 9 Sep, 2020.)

(Also see "Merck CEO Stresses Need For ‘Fair Return’ On COVID-19 Interventions" - Scrip, 7 Sep, 2020.)

(Also see "$2bn AbbVie Deal Puts I-Mab On Global Immuno-Oncology Map" - Scrip, 4 Sep, 2020.)

(Also see "Sanofi Showcases Long-Term Benefits Of Dupixent For Severe Asthma" - Scrip, 8 Sep, 2020.)

(Also see "Migraine Market Update: CGRP Inhibitors Slowly Gain Ground" - Scrip, 7 Sep, 2020.)

 

Related Content

Topics

UsernamePublicRestriction

Register

LL1133951

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel